var data={"title":"Carnitine supplements (Levocarnitine): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Carnitine supplements (Levocarnitine): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6451?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=carnitine-supplements-levocarnitine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Carnitine supplements (Levocarnitine): Patient drug information&quot;</a> and <a href=\"topic.htm?path=carnitine-supplements-levocarnitine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Carnitine supplements (Levocarnitine): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187916\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Carnitor;</li>\n      <li>Carnitor SF;</li>\n      <li>G-LevoCarnitine S/F [OTC];</li>\n      <li>McCarnitine [OTC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187917\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Carnitor</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187947\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Dietary Supplement</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187919\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Carnitine deficiency (primary or secondary):</b>  Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oral solution: Initial: 1,000 mg/day in divided doses (every 3 to 4 hours throughout the day); titrate slowly as needed to 1,000 to 3,000 mg/day in divided doses based on tolerance and therapeutic response; higher doses may be needed in some patients (administer only with caution)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tablet: 990 mg 2 to 3 times a day, depending on clinical response</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Carnitine deficiency (secondary):</b> IV: 50 mg/kg/day in divided doses (every 3 or 4 hours; no less than every 6 hours); subsequent doses in the range of 50 mg/kg/day or higher if clinically indicated (maximum reported dose: 300 mg/kg/day). In patients with severe metabolic crisis, a 50 mg/kg loading dose followed by an additional 50 mg/kg in divided doses over the next 24 hours may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Carnitine deficiency in patients with ESRD requiring dialysis:</b> IV: 10 to 20 mg/kg (dry body weight) after each dialysis session; guide dosage adjustments by trough (predialysis) levocarnitine concentrations. Evaluate clinical response at 3-month intervals and titrate to the lowest effective dose; therapy should be discontinued if no improvement is seen after 9 to 12 months of therapy (Eknoyan 2003).  <b>Note:</b> Current guidelines do not support the routine use of levocarnitine in dialysis patients (K/DOQI guidelines 2000); however, the National Kidney Foundation indicates levocarnitine therapy in patients with hyporesponsiveness to erythropoietin-based products, symptomatic intradialytic hypotension, NYHA functional class III-IV or ACC/AHA stage C-D heart failure or symptomatic cardiomyopathy, or muscle weakness and fatigability affecting quality of life which are unresponsive to standard medical therapy (Eknoyan 2003). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Valproic acid toxicity, acute (off-label use):</b> IV:  Initial: 100 mg/kg as an IV bolus followed by 50 mg/kg (maximum: 3,000 mg) as an IV bolus or intermittent infusion (over 15 to 30 minutes) every 8 hours; continue until ammonia levels are decreasing and clinical improvement is evident; patients may require several days of therapy (Perrott 2010).  Some experts recommend a higher maximum loading dose (eg, 100 mg/kg [maximum: 6,000 mg]) and smaller, more frequent maintenance doses (eg, 15 mg/kg every 4 to 6 hours) in symptomatic patients (Howland 2011; Russell 2007).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187936\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=carnitine-supplements-levocarnitine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Carnitine supplements (Levocarnitine): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Carnitine deficiency (primary or secondary):</b>  Infants, Children, and Adolescents: Oral: Initial: 50 mg/kg/day in divided doses; titrate slowly as needed to 50 to 100 mg/kg/day in divided doses based on tolerance and therapeutic response (maximum dose: 3,000 mg/day). <b>Note: </b>Oral solution doses should be spaced every 3 to 4 hours throughout the day.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Carnitine deficiency (secondary):</b> Infants, Children, and Adolescents: IV: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Carnitine deficiency in patients with ESRD requiring dialysis:</b> Infants, Children, and Adolescents: IV: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Valproic acid toxicity (off-label use):</b> IV:  Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187920\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16265530\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Oral: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied). However, safety and efficacy of oral carnitine have not been evaluated in patients with renal insufficiency. Chronic administration of high oral doses to patients with severely compromised renal function or ESRD patients on dialysis may result in accumulation of potentially toxic metabolites.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">IV:  There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; dosage adjustments should be determined by levocarnitine levels and clinical response. <b>Note:</b> Current guidelines do not support the routine use of levocarnitine in dialysis patients (K/DOQI guidelines 2000); however, the National Kidney Foundation indicates levocarnitine therapy in patients with hyporesponsiveness to erythropoietin-based products, symptomatic intradialytic hypotension, NYHA functional class III-IV or ACC/AHA stage C-D heart failure or symptomatic cardiomyopathy, or muscle weakness and fatigability affecting quality of life which are unresponsive to standard medical therapy (Eknoyan 2003).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16265531\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">Oral, IV: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187896\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Carnitor: 200 mg/mL (5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 200 mg/mL (5 mL [DSC], 12.5 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 200 mg/mL (5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Carnitor: 1 g/10 mL (118 mL) [contains methylparaben, propylparaben; cherry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Carnitor SF: 1 g/10 mL (118 mL) [sugar free; contains methylparaben, propylparaben, saccharin sodium; cherry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">G-LevoCarnitine S/F: 1 g/10 mL (474 mL) [sugar free; contains methylparaben, propylene glycol, propylparaben]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 g/10 mL (118 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Carnitor: 330 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">McCarnitine: 330 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mg, 330 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187881\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187899\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral solution: Solution is for oral use only (not for parenteral use); may be consumed alone or dissolved in either a drink or liquid food, and should be consumed slowly. Space doses every 3 to 4 hours evenly throughout the day, preferably during or following meals, to maximize tolerance.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IV: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Carnitine deficiency: Administer as a bolus dose over 2 to 3 minutes or by infusion. Doses should be administered every 3 to 4 hours, but never less than every 6 hours (eg, 4 doses/day).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hemodialysis patients: Administer as a bolus dose over 2 to 3 minutes into the venous return line after each dialysis session.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187898\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Carnitine deficiency in patients with end-stage renal disease requiring hemodialysis (injection only):</b> Prevention and treatment of carnitine deficiency in patients with end-stage renal disease (ESRD) who are undergoing dialysis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Dietary supplement (OTC only):</b> As a levocarnitine dietary supplement.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Primary systemic carnitine deficiency (oral [Rx] only):</b> Treatment of primary systemic carnitine deficiency.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Secondary carnitine deficiency (oral [Rx] and injection):</b> Acute and chronic treatment of patients with an inborn error of metabolism which results in a secondary carnitine deficiency.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25473348\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Elevated ammonia levels, coma, and/or hepatic dysfunction due to valproic acid overdose/toxicity</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187954\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">LevOCARNitine may be confused with levETIRAcetam, levocabastine</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187888\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequencies noted with hemodialysis patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Hypertension (intravenous: 18% to 21%), chest pain (intravenous: 15%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Headache (intravenous: 37%), dizziness (intravenous: 15% to 18%), paresthesia (intravenous: 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Endocrine &amp; metabolic: Hypercalcemia (intravenous: 6% to 15%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Diarrhea (intravenous: 35%), abdominal pain (intravenous: 21%), vomiting (intravenous: 21%), nausea (intravenous: 12%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hematologic &amp; oncologic: Anemia (intravenous: 5% to 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infection: Infection (intravenous: 24%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Weakness (intravenous: 9% to 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Cough (intravenous: 18%), rhinitis (intravenous: 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Miscellaneous: Accidental injury (intravenous: 12%), fever (intravenous: 6% to 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Tachycardia (intravenous: 6% to 9%), palpitations (intravenous: 3% to 8%), vascular disease (intravenous: 6%), peripheral edema (intravenous: 5% to 6%), ECG abnormality (intravenous: 3% to 6%), atrial fibrillation (intravenous: 2% to 6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Drug dependence (intravenous: 6%), vertigo (intravenous: 6%), depression (intravenous: 5% to 6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Skin rash (intravenous: 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Endocrine &amp; metabolic: Weight loss (intravenous: 8%), parathyroid disorder (intravenous: 6%), weight gain (intravenous: 3% to 6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Dysgeusia (intravenous: 2% to 9%), melena (intravenous: 6%), anorexia (intravenous: 5% to 6%), gastrointestinal disorder (intravenous: 3% to 6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hematologic &amp; oncologic: Hemorrhage (intravenous: 9%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hypersensitivity: Hypersensitivity reaction (intravenous: 6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ophthalmic: Amblyopia (intravenous: 6%), eye disease (intravenous: 3% to 6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Renal: Renal failure (intravenous: 6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Bronchitis (intravenous: 3% to 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Gastritis (intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Miscellaneous: Body odor</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%, postmarketing, and/or case reports: Abdominal cramps, change in prothrombin time, hypoglycemia, myasthenia (uremic patients), rhabdomyolysis, seizure, vitamin K deficiency</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14725394\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">There are no contraindications listed in the manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling: </i>Additional contraindications (not in US labeling): Hypersensitivity to levocarnitine or any component of the formulation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187885\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Gastrointestinal effects: GI reactions may result from too rapid consumption of oral carnitine; consume oral solution slowly and space doses evenly throughout the day to maximize tolerance.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Carnitine deficiency: Risk factors include: Age (infants and young children are deficient in the enzyme that activates carnitine), chronic valproic acid administration, concomitant neurologic disorders, congenital metabolic disorders, hepatic cirrhosis, renal failure, critical care patients (burns, sepsis, trauma, organ failure), use of multiple antiepileptic drugs and other drugs (chemotherapy agents, antinucleoside analogues) (Katiyar 2007). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Safety and efficacy of oral carnitine have not been evaluated in patients with renal insufficiency. Chronic administration of high oral doses to patients with severely compromised renal function or ESRD patients on dialysis may result in accumulation of potentially toxic metabolites. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Seizure disorder: Use with caution in patients with seizure disorders or in those at risk of seizures; both new-onset seizure activity as well as an increased frequency and/or severity of seizures has been observed. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299590\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6221274\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10109&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): LevOCARNitine may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187892\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187904\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Teratogenic effects were not observed in animal studies. Carnitine is a naturally occurring substance in mammalian metabolism.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187905\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">In breast-feeding women, use must be weighed against the potential exposure of the infant to increased carnitine intake. According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187894\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Carnitine concentrations (initially, weekly, and monthly for IV therapy)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Metabolic disorders: Monitor blood chemistry, vital signs, and plasma carnitine levels (maintain between 35 to 60 &mu;mol/L). In ESRD patients on dialysis: National Kidney Foundation guidelines recommend basing treatment on clinical signs and symptoms; evaluate response at 3-month intervals and discontinue if no clinical improvement noted within 9 to 12 months (Eknoyan 2003).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Valproic acid toxicity: Evaluate valproic acid concentrations (every 4 to 6 hours until a downward trend is observed), electrolytes, blood gases, mental status, hepatic function, serum ammonia concentration, serum lactate, and platelets.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187897\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Normal carnitine levels are 40 to 50 micromole/L; levels should be maintained on therapy between 35 to 60 micromole/L</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187884\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Carnitine is a naturally occurring metabolic compound which functions as a carrier molecule for long-chain fatty acids within the mitochondria, facilitating energy production. Carnitine deficiency is associated with accumulation of excess acyl CoA esters and disruption of intermediary metabolism.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187901\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: None</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic; Major metabolites: Trimethylamine (TMA) and trimethylamine N-oxide (TMAO)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Oral solution: 15.9% &plusmn; 4.9%; Tablet: 15.1% &plusmn; 5.3%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 17.4 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: Oral: 3.3 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (76%, 4% to 8% as unchanged drug); feces (&lt;1%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187903\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Acticarnitine SF Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g/10 mL (474 mL): $23.76</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Carnitor Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg/mL (5 mL): $39.74</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Carnitor Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g/10 mL (118 mL): $39.60</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Carnitor SF Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g/10 mL (118 mL): $49.20</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (LevOCARNitine Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g/10 mL (118 mL): $46.31</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Carnitor Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">330 mg (90): $106.20</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (L-Carnitine Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (90): $31.49</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (LevOCARNitine (Dietary) Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">330 mg (90): $28.20</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (LevOCARNitine Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">330 mg (90): $98.75</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (McCarnitine Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">330 mg (90): $15.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187906\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Abedine (JP);</li>\n      <li>Albicar (AR);</li>\n      <li>Almiba (UA);</li>\n      <li>Bio-Carnitine (BE);</li>\n      <li>Biocarn (CH, DE);</li>\n      <li>Branigen (IT);</li>\n      <li>Cardimax (PH);</li>\n      <li>Cardispan (MX);</li>\n      <li>Carnicor (ES, PH);</li>\n      <li>Carnil (GR, RO);</li>\n      <li>Carnin (KR);</li>\n      <li>Carnitene (CH, HR, NL, TW);</li>\n      <li>Carnitina (AR);</li>\n      <li>Carnitor (BD, GB);</li>\n      <li>Carnivit (PL);</li>\n      <li>Carry FA (KR);</li>\n      <li>Cartan (CN);</li>\n      <li>Cartin (PH);</li>\n      <li>Cartine (BD, PH);</li>\n      <li>Chudex (PL);</li>\n      <li>Disocor (PT);</li>\n      <li>Efe-Carn (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Elcarnitol (CH);</li>\n      <li>Entomin (JP);</li>\n      <li>Fitmax L-Karnityna (PL);</li>\n      <li>Hardbody L-Karnityna (PL);</li>\n      <li>Karniten (UA);</li>\n      <li>L-Cadul (KR);</li>\n      <li>L-Carn (KR);</li>\n      <li>L-Carnitin (AT, CZ, PL);</li>\n      <li>L-Cartin FF (JP);</li>\n      <li>L-Karnityna (PL);</li>\n      <li>Lecarna (MT);</li>\n      <li>Levocar (BD);</li>\n      <li>Levocarnil (FR);</li>\n      <li>Monocamin (JP);</li>\n      <li>Nefrocarnit (EE, TR);</li>\n      <li>Neurex (AR);</li>\n      <li>Neuroactil (AR);</li>\n      <li>Ocarnix (BD);</li>\n      <li>Secabiol (ES);</li>\n      <li>Steatel (UA);</li>\n      <li>Trian (TR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Carnitor Oral Solution and Tablets (levocarnitine) [prescribing information]. Gaithersburg, MD: Sigma-Tau Pharmaceuticals Inc; June 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Carnitor Injection (levocarnitine) [prescribing information]. Gaithersburg, MD: Sigma-Tau Pharmaceuticals Inc; June 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Carnitor (levocarnitine) [product monograph]. Scarborough, Ontario, Canada: Leadiant Biosciences Inc; November 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eknoyan G, Latos DL, and Lindberg J, &ldquo;Practice Recommendations for the Use of L-Carnitine in Dialysis-Related Carnitine Disorder. National Kidney Foundation Carnitine Consensus Conference,&rdquo; <i>Am J Kidney Dis</i>, 2003, 41(4):868-76<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carnitine-supplements-levocarnitine-drug-information/abstract-text/12666074/pubmed\" target=\"_blank\" id=\"12666074\">12666074</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16012283\"></a>Eyer F, Felgenhauer N, Gempel K, et al, &quot;Acute Valproate Poisoning: Pharmacokinetics, Alteration in Fatty Acid Metabolism, and Changes During Therapy,&quot; <i>J Clin Psychopharmacol</i>, 2005, 25(4):376-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carnitine-supplements-levocarnitine-drug-information/abstract-text/16012283/pubmed\" target=\"_blank\" id=\"16012283\">16012283</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Howland MA. Antidotes in depth: L-carnitine. In: Nelson L, Lewin N, Howland MA, Hoffman R, Goldfrank L, Flomenbaum N. <i>Goldfrank&rsquo;s Toxicologic Emergencies</i>. 9th ed. New York, NY: McGraw-Hill Companies, Inc; 2011:711.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Katiyar A and Aaron C, &quot;Case Files of the Children's Hospital of Michigan Regional Poison Control Center: The Use of Carnitine for the Management of Acute Valproic Acid Toxicity,&quot; <i>J Med Toxicol</i>, 2007, 3(3):129-38.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carnitine-supplements-levocarnitine-drug-information/abstract-text/18072149/pubmed\" target=\"_blank\" id=\"18072149\">18072149</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22180549\"></a>Mock CM and Schwetschenau KH, &quot;Levocarnitine for Valproic Acid-Induced Hyperammonemic Encephalopathy,&quot; <i>Am J Health Syst Pharm</i>, 2012, 69(1):35-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carnitine-supplements-levocarnitine-drug-information/abstract-text/22180549/pubmed\" target=\"_blank\" id=\"22180549\">22180549</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Kidney Foundation, &ldquo;Clinical Practice Guidelines for Nutrition in Chronic Renal Failure. K/DOQI,&rdquo; <i>Am J Kidney Dis</i>, 2000, 35(6 Suppl 2):1-140.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carnitine-supplements-levocarnitine-drug-information/abstract-text/10895784/pubmed\" target=\"_blank\" id=\"10895784\">10895784</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20587742\"></a>Perrott J, Murphy NG, and Zed PJ, &quot;L-Carnitine for Acute Valproic Acid Overdose: A Systematic Review of Published Cases,&quot; <i>Ann Pharmacother</i>, 2010, 44(7-8):1287-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carnitine-supplements-levocarnitine-drug-information/abstract-text/20587742/pubmed\" target=\"_blank\" id=\"20587742\">20587742</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17496767\"></a>Russell S, &quot;Carnitine as an Antidote for Acute Valproate Toxicity in Children,&quot; <i>Curr Opin Pediatr</i>, 2007, 19(2):206-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carnitine-supplements-levocarnitine-drug-information/abstract-text/17496767/pubmed\" target=\"_blank\" id=\"17496767\">17496767</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schreiber B, &ldquo;Levocarnitine and Dialysis: A Review,&rdquo; <i>Nutr Clin Pract</i>, 2005, 20(2):218-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carnitine-supplements-levocarnitine-drug-information/abstract-text/16207659/pubmed\" target=\"_blank\" id=\"16207659\">16207659</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10109 Version 130.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F187916\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F187917\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F187947\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F187919\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F187936\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F187920\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F16265530\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F16265531\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F187896\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F187881\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F187899\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F187898\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25473348\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F187954\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F187888\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F14725394\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F187885\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299590\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6221274\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F187892\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F187904\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F187905\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F187894\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F187897\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F187884\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F187901\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F187903\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F187906\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10109|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=carnitine-supplements-levocarnitine-patient-drug-information\" class=\"drug drug_patient\">Carnitine supplements (Levocarnitine): Patient drug information</a></li><li><a href=\"topic.htm?path=carnitine-supplements-levocarnitine-pediatric-drug-information\" class=\"drug drug_pediatric\">Carnitine supplements (Levocarnitine): Pediatric drug information</a></li></ul></div></div>","javascript":null}